Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials

被引：43

作者：

Broadbent, Lindsay ^{[1
]}

Groves, Helen ^{[1
]}

Shields, Michael D. ^{[1
,2
]}

Power, Ultan F. ^{[1
]}

机构：

[1] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Infect & Immun, Belfast BT9 7BL, Antrim, North Ireland

[2] Royal Belfast Hosp Sick Children, Belfast, Antrim, North Ireland

来源：

INFLUENZA AND OTHER RESPIRATORY VIRUSES | 2015年 / 9卷 / 04期

关键词：

respiratory syncytial virus; respiratory syncytial virus antivirals; respiratory syncytial virus prophylactic antibodies; respiratory syncytial virus vaccines; VACCINE CANDIDATE; DISEASE SEVERITY; FUSION PROTEIN; NEUTRALIZING ANTIBODIES; HUMAN METAPNEUMOVIRUS; MONOCLONAL-ANTIBODY; VIRAL LOAD; RSV F; INFANTS; LIVE;

D O I：

10.1111/irv.12313

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

As the most important viral cause of severe respiratory disease in infants and increasing recognition as important in the elderly and immunocompromised, respiratory syncytial virus (RSV) is responsible for a massive health burden worldwide. Prophylactic antibodies were successfully developed against RSV. However, their use is restricted to a small group of infants considered at high risk of severe RSV disease. There is still no specific therapeutics or vaccines to combat RSV. As such, it remains a major unmet medical need for most individuals. The World Health Organisations International Clinical Trials Registry Platform (WHO ICTRP) and PubMed were used to identify and review all RSV vaccine, prophylactic and therapeutic candidates currently in clinical trials. This review presents an expert commentary on all RSV-specific prophylactic and therapeutic candidates that have entered clinical trials since 2008.

引用

页码：169 / 178

页数：10

共 82 条

[1] Gene therapies for inherited skin disorders [J].